Ani Pharmaceuticals (ANIP) Cash & Equivalents (2010 - 2026)

Ani Pharmaceuticals has disclosed Cash & Equivalents across 17 years of filings, most recently posting $360.2 million for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 65.36% year-over-year to $360.2 million; the TTM figure through Jun 2026 stood at $360.2 million (up 65.36% YoY), while the FY2025 annual figure was $285.6 million, up 97.1% from the prior year.
• Cash & Equivalents came in at $360.2 million for Q2 2026 at Ani Pharmaceuticals, up from $311.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $360.2 million in Q2 2026 to a low of $48.2 million in Q4 2022.
• Average Cash & Equivalents over 5 years is $179.7 million, with a median of $177.4 million recorded in 2023.
• Year-over-year, Cash & Equivalents slumped 51.92% in 2022 and surged 358.49% in 2023.
• Over 5 years, Cash & Equivalents stood at $48.2 million in 2022, then soared by 358.49% to $221.1 million in 2023, then sank by 34.47% to $144.9 million in 2024, then jumped by 97.1% to $285.6 million in 2025, then increased by 26.13% to $360.2 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $360.2 million in Q2 2026, $311.2 million in Q1 2026, and $285.6 million in Q4 2025.